NCT02821338View on ClinicalTrials.gov

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

April 30, 2017

Conditions
Healthy
Interventions
DRUG

Lamotrigine Extended Release

Lamotrigine Extended Release (generic) and Lamictal XR (brand).

Trial Locations (1)

66212

Vince and Associates Clinical Research, Inc, Overland Park

Sponsors

Collaborators (1)

Algorithme Pharma Inc
All Listed Sponsors
collaborator

Vince & Associates Clinical Research, Inc.

OTHER

collaborator

Algorithme Pharma Inc

INDUSTRY

lead

Food and Drug Administration (FDA)

FED

NCT02821338 - A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter